	US 12,453,715 B2
	Use of artemether in the prevention and treatment of Alzheimer's disease
Wenhua Zheng, Macao (CN)
Assigned to UNIVERSITY OF MACAU, Macao (CN)
Filed by UNIVERSITY OF MACAU, Macao (CN)
Filed on Mar. 19, 2021, as Appl. No. 17/206,420.
Application 17/206,420 is a continuation in part of application No. PCT/CN2018/113458, filed on Nov. 1, 2018.
Claims priority of application No. 201811169454.6 (CN), filed on Oct. 8, 2018.
Prior Publication US 2021/0205265 A1, Jul. 8, 2021
Int. Cl. A61K 31/357 (2006.01); A61P 25/28 (2006.01)

CPC A61K 31/357 (2013.01) [A61P 25/28 (2018.01)]

4 Claims

1. A method for the treatment of diseases related to insufficiency of AMPK phosphorylation and GSK-3β (ser9) phosphorylation in a subject in need thereof, comprising: administering artemether to the subject; wherein the diseases related to insufficiency of AMPK phosphorylation and GSK-3β (ser9) phosphorylation comprise one or more selected from the group consisting of pulmonary infectious diseases and pulmonary fibrosis, and the dosage of artemether is about 0.1 mg/kg body weight/day to about 20 mg/kg body weight/day.